812 related articles for article (PubMed ID: 21256189)
1. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
van Dissel JT; Soonawala D; Joosten SA; Prins C; Arend SM; Bang P; Tingskov PN; Lingnau K; Nouta J; Hoff ST; Rosenkrands I; Kromann I; Ottenhoff TH; Doherty TM; Andersen P
Vaccine; 2011 Mar; 29(11):2100-9. PubMed ID: 21256189
[TBL] [Abstract][Full Text] [Related]
2. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.
van Dissel JT; Arend SM; Prins C; Bang P; Tingskov PN; Lingnau K; Nouta J; Klein MR; Rosenkrands I; Ottenhoff TH; Kromann I; Doherty TM; Andersen P
Vaccine; 2010 Apr; 28(20):3571-81. PubMed ID: 20226890
[TBL] [Abstract][Full Text] [Related]
3. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
Badell E; Nicolle F; Clark S; Majlessi L; Boudou F; Martino A; Castello-Branco L; Leclerc C; Lewis DJ; Marsh PD; Gicquel B; Winter N
Vaccine; 2009 Jan; 27(1):28-37. PubMed ID: 18977269
[TBL] [Abstract][Full Text] [Related]
4. Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice.
Luo Y; Wang B; Hu L; Yu H; Da Z; Jiang W; Song N; Qie Y; Wang H; Tang Z; Xian Q; Zhang Y; Zhu B
Vaccine; 2009 Oct; 27(44):6179-85. PubMed ID: 19712772
[TBL] [Abstract][Full Text] [Related]
5. An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis.
Wang QL; Pan Q; Ma Y; Wang K; Sun P; Liu S; Zhang XL
Vaccine; 2009 Nov; 27(48):6712-22. PubMed ID: 19733584
[TBL] [Abstract][Full Text] [Related]
6. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
[TBL] [Abstract][Full Text] [Related]
8. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
Andersen CS; Dietrich J; Agger EM; Lycke NY; Lövgren K; Andersen P
Infect Immun; 2007 Jan; 75(1):408-16. PubMed ID: 17074845
[TBL] [Abstract][Full Text] [Related]
9. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.
Skeiky YA; Dietrich J; Lasco TM; Stagliano K; Dheenadhayalan V; Goetz MA; Cantarero L; Basaraba RJ; Bang P; Kromann I; McMclain JB; Sadoff JC; Andersen P
Vaccine; 2010 Jan; 28(4):1084-93. PubMed ID: 19896449
[TBL] [Abstract][Full Text] [Related]
10. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
11. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells.
Lindenstrøm T; Agger EM; Korsholm KS; Darrah PA; Aagaard C; Seder RA; Rosenkrands I; Andersen P
J Immunol; 2009 Jun; 182(12):8047-55. PubMed ID: 19494330
[TBL] [Abstract][Full Text] [Related]
12. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.
van Dissel JT; Joosten SA; Hoff ST; Soonawala D; Prins C; Hokey DA; O'Dee DM; Graves A; Thierry-Carstensen B; Andreasen LV; Ruhwald M; de Visser AW; Agger EM; Ottenhoff TH; Kromann I; Andersen P
Vaccine; 2014 Dec; 32(52):7098-107. PubMed ID: 25454872
[TBL] [Abstract][Full Text] [Related]
13. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant.
Kamath AT; Rochat AF; Valenti MP; Agger EM; Lingnau K; Andersen P; Lambert PH; Siegrist CA
PLoS One; 2008; 3(11):e3683. PubMed ID: 18997860
[TBL] [Abstract][Full Text] [Related]
14. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis.
Bennekov T; Dietrich J; Rosenkrands I; Stryhn A; Doherty TM; Andersen P
Eur J Immunol; 2006 Dec; 36(12):3346-55. PubMed ID: 17109467
[TBL] [Abstract][Full Text] [Related]
15. T-cell and serological responses to Erp, an exported Mycobacterium tuberculosis protein, in tuberculosis patients and healthy individuals.
Martinez V; Carcelain G; Badell E; Jouan M; Mauger I; Sellier P; Truffot C; Bricaire F; Arend SM; Ottenhoff T; Autran B; Gicquel B
BMC Infect Dis; 2007 Jul; 7():83. PubMed ID: 17655752
[TBL] [Abstract][Full Text] [Related]
16. Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice.
Xu Y; Zhu B; Wang Q; Chen J; Qie Y; Wang J; Wang H; Wang B; Wang H
FEMS Immunol Med Microbiol; 2007 Dec; 51(3):480-7. PubMed ID: 17919299
[TBL] [Abstract][Full Text] [Related]
17. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection.
Lin PL; Dietrich J; Tan E; Abalos RM; Burgos J; Bigbee C; Bigbee M; Milk L; Gideon HP; Rodgers M; Cochran C; Guinn KM; Sherman DR; Klein E; Janssen C; Flynn JL; Andersen P
J Clin Invest; 2012 Jan; 122(1):303-14. PubMed ID: 22133873
[TBL] [Abstract][Full Text] [Related]
18. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis.
Tang C; Yamada H; Shibata K; Maeda N; Yoshida S; Wajjwalku W; Ohara N; Yamada T; Kinoshita T; Yoshikai Y
J Infect Dis; 2008 May; 197(9):1263-74. PubMed ID: 18422438
[TBL] [Abstract][Full Text] [Related]
20. Subunit vaccine candidate AMM down-regulated the regulatory T cells and enhanced the protective immunity of BCG on a suitable schedule.
Luo Y; Jiang W; Da Z; Wang B; Hu L; Zhang Y; An R; Yu H; Sun H; Tang K; Tang Z; Wang Y; Jing T; Zhu B
Scand J Immunol; 2012 Mar; 75(3):293-300. PubMed ID: 22117839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
